fbpx
Wed. Apr 24th, 2024

First of its kind therapy approved for reducing LDL cholesterol. siRNA Therapy reduced LDL by 50%

By Owner Dec 13, 2022

First of its kind therapy approved for reducing LDL cholesterol. Leqvio, aka Inclisiran, is the first small interfering RNA (siRNA) therapy to hit the market for treating atherosclerotic cardiovascular disease. The regimen consists of an initial subcutaneous injection, another at three months, then a maintenance dose every six months. This treatment reduced LDL by 50%

By Owner

Related Post

Social media & sharing icons powered by UltimatelySocial
error

Enjoy this blog? Please spread the word :)